Britannia Life Sciences Inc.
BLAB
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.97M | 5.25M | 5.34M | 5.45M | 5.62M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.97M | 5.25M | 5.34M | 5.45M | 5.62M |
| Cost of Revenue | 1.41M | 1.41M | 1.33M | 1.31M | 1.24M |
| Gross Profit | 2.56M | 2.56M | 2.72M | 2.86M | 3.09M |
| SG&A Expenses | 2.15M | 2.15M | 2.16M | 2.49M | 2.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.55M | 4.59M | 4.53M | 4.84M | 4.66M |
| Operating Income | 414.40K | 658.50K | 805.00K | 614.30K | 957.40K |
| Income Before Tax | -1.21M | -1.21M | -906.30K | 445.20K | 1.12M |
| Income Tax Expenses | 142.50K | 142.50K | 135.50K | 129.90K | 248.30K |
| Earnings from Continuing Operations | -1.35 | -1.35 | -1.04 | 0.32 | 0.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -161.70K | -161.70K | 20.10K | 78.70K | -24.60K |
| Net Income | -1.51M | -5.90M | -5.40M | -3.99M | -3.54M |
| EBIT | 414.40K | 658.50K | 805.00K | 614.30K | 957.40K |
| EBITDA | 469.30K | 717.20K | 894.40K | 738.20K | 1.11M |
| EPS Basic | -0.01 | -0.04 | -0.03 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.04 | -0.03 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 649.02M | 649.02M | 649.02M | 649.02M | 649.02M |
| Average Diluted Shares Outstanding | 649.02M | 649.02M | 649.02M | 649.02M | 649.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |